The Type 1 Diabetes Resource
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at NIH is funding the Type 1 Diabetes Resource (T1DR) at The Jackson Laboratory.
The purpose of this resource is to collect and cryopreserve 20-30 mouse stocks per year important to research in type 1 diabetes.
An advisory committee oversees the selection of stocks to be included in the T1DR.
The resource includes:
- NOD stocks carrying transgenes
- Targeted mutations (e.g. gene knockouts)
- NOD and NOD-related stocks congenic for chromosomal intervals containing T1D susceptibility or resistance loci
- Mouse models important to Type 1 Diabetes research
- Resources useful for the transplant of human stem cells and other tissues
- The T1DR includes stocks donated by external investigators and stocks generated at The Jackson Laboratory.
An online form is available for investigators wishing to donate a stock. We are also soliciting suggestions for stocks that should be included in the T1DR.
Although the primary mission of the T1DR is cryopreservation of valuable mouse stocks, provisions are being made for each stock to be available for live distribution over a limited period of time.
If you wish to be notified when various stocks are available for live distribution, please contact the project manager.
Available: Incidence Studies
Our Expanded Mission:
Most of the morbidity and mortality ascribed to chronic diabetes whether it be T1D or Type 2 diabetes, results from development of secondary complications: diabetic nephropathy, neuropathy, or cadiovascular disease developing singly or in combinations. Although the T1DR and The Jackson Laboratory have excellent mouse models developing both forms of diabetes, these mice are remarkably resistant to development of complications accurately reflecting those seen in human patients. In February, 2007, the T1DR, through a contract with NIDDK, expanded its mission to serve as the Mouse Generation and Husbandry Core (MGHC) for the Animal Models of Diabetes Complications Consortium (AMDCC). The mission of the AMDCC is to coordinate efforts to produce by genetic engineering techniques the development of human like diabetic complications in diabetic mice, including diabetic kidney disease, vascular disease, retinopathy, neuropathy, and diabetic cardiomyopathy. To complement that mission, the T1DR will use its expertise in analyzing diabetic mice to maintaine, expand, phenotype and distribute new complications-prone diabetic strains established in cooperation with the AMDCC. The T1DR works closely with the AMDCC investigators to introduce 5-10 genetic maniulations per year into diabetes-developing strains. The T1DR works both with the AMDCC investigator and the relevant Mouse Metabolic Phenotyping Center (MMPC) to establish baseline development of complications in a given diabetes model, and whether any genetic manibulations performed incresed susceptibility to complications. Additionally, T1DR staff advise the AMDCC investigators in regard to newly-imported JAX Mice strains that may be sensitized to diabetes complications.
